European agreement adds four new products across additional therapeutic areas taking total up to 17
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’) the global pharmaceutical and services company, announces that its global leading Clinical Trial Services business (Clinigen CTS) has renewed an exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare (‘Accord’), a wholly-owned marketing subsidiary of Intas Pharmaceuticals, for a further two years.
The agreement has also been extended to include four new products including the solid dose oncology drug temozolomide and Accord’s first biosimilar, Accofil® (filgrastim) for the treatment of chemotherapy-induced neutropenia (an abnormally low number of neutrophil white blood cells). For the first time, the agreement has been expanded to include drugs from additional therapeutic areas including diabetes (glimepiride) and transplant rejection (mycophenelate).
Clinigen CTS has partnered with Accord since 2012 to deliver its oncology products, including cisplatin, cytarabine, docetaxel, doxorubicin and fluorouracil, into clinical trials. The CTS team is the sole point of contact for all clinical trial supply enquiries, and distributes Accord’s products to manufacturers, contract research organizations (CROs), clinical trial contract packagers and other specialist service providers. The drugs are supplied for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.
Daniel Green, Regional Director UK & Ireland at Accord said: “We have been impressed with the service provided by Clinigen CTS since 2012 and are pleased to be able to continue and extend our exclusive agreement with an additional four new products. The partnership has enabled us to maximise the impact of our products in clinical trials which we see as an important area.”
Steve Glass, Group Managing Director, Clinigen Group said: “Clinigen is committed to providing the best possible clinical trial service and distribution capabilities. This has been demonstrated by both the continuation of this strong partnership and Accord’s decision to extend the agreement to include four more key products. We are pleased to be working with the Accord team for another two years.”